CVS Health (CVS)
NYSEHealth CareMedical - Healthcare PlansSnapshot 2026-09-04
$96.74-0.47%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - Healthcare PlansSnapshot 2026-09-04
Research Workspace
Put CVS beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care is in expansion. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar broken — Adjusted EPS guidance raised to $7.30 per share in 2026: FY26 EPS guidance mid $6.94 vs $7.30 target.
View ThesisRevenue is growing steadily — about 7% over the past year.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityMiddle-of-the-pack management execution.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskCVS's growth trajectory relies on its ability to maintain strong revenue and earnings growth. Revenue is currently growing at 7.4% year over year, and management raised full-year 2026 adjusted EPS guidance to a range of $7.90 to $8.10. CVS trades at 12× P/E, which is below the peer median of 23×. This suggests that the price reflects less growth than we forecast. The primary risk is a potential credibility hit if CVS cuts guidance after recently raising it, which our model puts at a 10% probability of a miss next quarter. Peer multiples imply a price about 12% above where it trades. Our read remains provisional.
Trailing returns as of 2026-09-04. CVS is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 27 analysts currently covering CVS (as of Sep 2026).
Based on 13 Wall Street analysts offering 12-month price targets for CVS in the last 4 months.
Continue this research
Compare CVS with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| CVS Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 12 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Services — fair value, gap to price, and forward P/E.
Compare the value case
Put CVS next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Advance Health Care Benefits segment margin recovery
New tools enhance Health Care Benefits segment margin recovery.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-04. EPS is implied from price ÷ P/E. Not investment advice.
Current $96.74
The last 12 months of price, then the range of analyst 12-month targets from today’s $96.74.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Around the middle on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Regulatory scrutiny could impact CVS's operational strategy.
Advances: Increase adjusted EPS guidance
Positive outlook supports growth and EPS guidance.
Sell-off indicates investor concerns about future earnings risks.
Threatens: Maintain revenue guidance of at least $400 billion
Raising guidance may indicate operational challenges ahead.
Advances: Increase adjusted EPS guidance
Stronger results support increased adjusted EPS guidance.
Advances: Increase adjusted EPS guidance
Strong earnings beat supports increased adjusted EPS guidance.
Advances: Increase adjusted EPS guidance
Increased EPS guidance supports growth objectives.
